Home › Compare › NIPMY vs ABBV
NIPMY yields 2.24% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, NIPMY + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of NIPMY + ABBV for your $10,000?
NH Foods Ltd. engages in the meat processing and packing business in Japan and internationally. The company's Processed Foods Business division offers hams and sausages primarily under the SCHAU ESSEN and Utsukushi-no-Kuni brands; and deli and processed foods primarily under the Chuka Meisai and Ishigama Kobo brand names. Its Fresh Meats Business division is involved in the production and raising, slaughtering, processing, distribution, and sale of fresh meat products. The company's Affiliated Business division produces and sells marine products and dairy products. This segment procures, processes, produces, and sells marine products, such as seafood salads, Chinese jellyfish, and other delicacies, as well as mackerels to supermarkets, restaurants, and other customers; and offers cheese products under the ROLF brand name to bakeries, confectionery makers, and convenience store chains, as well as yogurt and lactic acid probiotic beverages under the Luna brand name. It also engages in the provision of freeze-dried foods, meat extracts, and health foods; and information, accounting, personnel system design, human resource development, welfare programs, and architectural design services, as well as trading and sports activities. The company was formerly known as Nippon Meat Packers Inc. and changed its name to NH Foods Ltd. in June 2014. NH Foods Ltd. was founded in 1942 and is headquartered in Osaka, Japan.
Full NIPMY Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.